Dr. Ruan on Lenalidomide Plus Rituximab in MCL

Video

In Partnership With:

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell, NewYork-Presbyterian Hospital, discusses the combination of lenalidomide (Revlimid) plus rituximab (Rituxan) in mantle cell lymphoma.

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the combination of lenalidomide (Revlimid) plus rituximab (Rituxan) in mantle cell lymphoma (MCL).

The 5-year follow-up and correlative analysis from a phase II multi-center study of lenalidomide plus rituximab as initial treatment for patients with MCL was presented at the 2017 ASH Annual Meeting.

Ruan says that the aim of this study was to explore potential chemotherapy-free options for this patient population.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD